GRAL Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -1.94%, SMA50 2.23%, SMA200 61.3%). The stock’s 14-day RSI is 50.42 (neutral), while the ATR of 7.86 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.52% below its high and over 391.19% above its low. Average 10-day trading volume of 697.39 thousand shares is below the 3-month average of 916.78 thousand, indicating normal recent market interest.

GRAIL, Inc. has 36.05 million shares outstanding. The public float is 24.18 million shares, elevated short interest at 15.40% of float. This equals 4.81 million shares. The short ratio is 4.38 days. Institutional investors hold 85.03% of the float. Insiders own 13.81%. ILLUMINA, INC. holds 3.50 million shares, DING CHUN R has 3.31 million shares and RAGUSA ROBERT P has 688.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.16 million shares across 12 transactions.

GRAIL, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$69.82. This means the shares are trading below this model’s fair value.

GRAIL, Inc. (NASDAQ:GRAL) closed at $100.40 USD, gaining $0.33 (0.33%) from the previous close of $100.07. The stock is currently mid-range between its 52-week high and low $20.44 and $118.84. With a market capitalization of about $3.91 billion, GRAIL, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~4.55). Key stats such as the average daily volume over the past year has been around 937.18 thousand shares, volume is running light vs its 52-week average. Headquartered in Menlo Park, CA, GRAIL, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Robert Ragusa, the company employs approximately 1,000 people and listed since June 12, 2024. GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.

GRAIL, Inc. generated EPS of -$11.61 over the past year. Five-year average earnings growth is -89.93%. Wall Street analysts project EPS growth of 43.71% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $130.00 to $20.00. The high target offers 29.48% upside. The low target suggests -80.08% downside. The mean target is $89.29. This offers -11.07% upside. GRAIL, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -27.56%. The prior quarter beat by 1.27%. Over the last six quarters, Apple has recorded several small beats. These include -38.72% in November 12, 2024.

GRAIL, Inc. trades at a P/E ratio of -8.91, slightly below the S&P 500 average, with a price-to-sales ratio of 27.53 and a price-to-book ratio of 1.62 suggesting the stock is closer to book value. The P/FCF stands at -11.84, also above market averages.

GRAIL, Inc. (NASDAQ:GRAL) shares are up 18.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows GRAIL, Inc. trading at a premium to the broader market with a P/E of -8.91. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $80.12, suggesting -20.2% downside. Our AI forecast model points to short-term strength (4.34% over two weeks), a medium-term rise (71.91% over three months), and a longer-term gain (59.66% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that GRAIL, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.34%, with price expected at $104.76 by February 23, 2026, within a range of $98.63 to $110.73 3-Month Outlook: Projected rise of 71.91%, reaching $172.60 by May 07, 2026, with a range of $171.16 to $173.74. 1-Year Outlook: Projected gain of 59.66%, with price at $160.30 by February 09, 2027, within a range of $154.38 to $165.70.